#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Familial dilated cardiomyopathy Anaplastic thyroid cancer Microscopic polyangiitis Cystic fibrosis Glycogen storage disease type II Craniocerebral injury Canavan disease Follicular lymphoma Autoimmune hepatitis Behcet's syndrome Cold type haemolytic anaemia Raynaud's phenomenon Eosinophilic granulomatosis with polyangiitis Deafness neurosensory Thromboangiitis obliterans More trials…

    Learn about Rare Diseases

    Hepatic angiosarcoma – Diagnostics Systemic mastocytosis Wolfram syndrome – Diagnostics Medulloblastoma – Basic Information Pituitary-dependent Cushing’s syndrome – Life with Disease Aicardi-Goutieres syndrome – Treatment Basal cell naevus syndrome – Basic Information Friedreich’s ataxia – Trials in Disease Immunodeficiency congenital – Trials in Disease Piriformis syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sodium Gluconate Clebopride Hydrogen Maleate Rilzabrutinib Desflurane FRUQUINTINIB AB521 Filgotinib R2R01 Avacopan Belzupacap Sarotalocan Neob Omp64 Daunorubicin Prasinezumab Insulin Icodec Minocycline Hydrochloride Opium, Standardized Powdered VAMIFEPORT TRIHYDROCHLORIDE Atomoxetine Histamine Dihydrochloride More therapies…

    Learn about Your Condition

    Choreoathetosis Bipolar disorder Cholangitis sclerosing Torticollis Exfoliation glaucoma Lung neoplasm malignant Multiple system atrophy Escherichia infection Nodal osteoarthritis Food allergy Anal incontinence Prinzmetal angina Plasma cell leukaemia Bile duct cancer Encephalitis Japanese B More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Phase 3 Study of Romiplostim Combined with Prednisolone versus Prednisolone Alone in Adults with Previously Untreated Primary Immune Thrombocytopenia (ITP)

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Immune thrombocytopenia
    Investigated Drugs:
    • Romiplostim
    • Prednisolone
    Germany Hungary Spain

  • A Phase 2 Study of TML-6 in Adults with Early Alzheimer’s Disease to Evaluate Safety, Tolerability, and Efficacy

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Sweden

  • Feasibility of Sequential Radium Ra-223 Dichloride After Triplet Therapy in High‑Volume Metastatic Hormone‑Sensitive Prostate Cancer Patients (Phase II)

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Radium Ra 223 Dichloride
    Spain

  • Advanced hepatocellular carcinoma patients: assessing atezolizumab drug combination and other treatment sequences

    Not yet recruiting

    4 1 1 1
    Investigated Drugs:
    • Cabozantinib
    • Regorafenib
    • Sorafenib
    Italy

  • Phase II Study of [68Ga]Ga-FAP-2286 PET/CT for Staging and Restaging Newly Diagnosed Primary Breast Cancer Patients

    Not yet recruiting

    2 1 1
    Denmark

  • Evaluation of zongertinib, fulvestrant and goserelin acetate in patients with HR‑positive HER2‑negative advanced breast cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Goserelin Acetate
    • Zongertinib
    • Fulvestrant
    Germany Italy Spain
Previous Page
1 … 664 665 666 667 668 … 1,657
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!